Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17983801 | 1.00 | ECE1 (0.32) | ECE1ALDH1A1TDP1 | |
| SCHEMBL19210879 | 1.00 | ECE1 (0.32) | ECE1ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL30322882 | 0.98 | ECE1 (0.32) | ECE1 | |
| Ethyl Acetate SCHEMBL27837018 | 0.83 | ALDH1A1 (0.48) | ALDH1A1TDP1 | |
| SCHEMBL1492543 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TDP1 | |
| SCHEMBL1902452 | 0.77 | SLC22A6 (0.39) | ALDH1A1TDP1 | |
| SCHEMBL12019810 | 0.77 | ALDH1A1 (0.50) | ALDH1A1TDP1 | |
| SCHEMBL19554508 | 0.77 | ECE1 (0.37) | ECE1ALDH1A1TDP1 | |
| SCHEMBL30782438 | 0.77 | SLC22A6 (0.39) | ALDH1A1TDP1 | |
| SCHEMBL191972 | 0.77 | SLC22A6 (0.39) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4408530-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2024-08-07 | — | — | EP | disclosed |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-02 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023049888-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | WO | disclosed |
| CN-115867348-A | Imidazopyrimidines as IL-17 modulators | 詹森药业有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-110809467-B | Modulators of SESTRIN-GATOR2 interactions and uses thereof | 纳维托制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| EP-4143195-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | Janssen Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2021222404-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN BIOTECH, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-104710327-B | It is beneficial to treat the compound of central nervous system disease and illness | 奥里梅德制药公司 | 2018-09-07 | — | — | CN | disclosed |
| CN-104710327-A | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA INC | 2015-06-17 | — | — | CN | disclosed |
| CN-102164488-B | Novel compounds useful in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA INC | 2015-02-25 | — | — | CN | disclosed |
| US-8871767-B2 | 2-arylimidazo[1,2-B]pyridazine, 2-phenylimidazo[1,2-A]pyridine, and 2-phenylimidazo[1,2-A]pyrazine derivatives | HENGRUI (USA) LTD. (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2635578-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | Hengrui (USA) Ltd. (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | HENGRUI (USA), LTD. | 2012-07-12 | — | — | US | disclosed |
| WO-2012088411-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PAMLICO PHARMACEUTICAL INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| CN-102164488-A | Novel compounds useful in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA INC | 2011-08-24 | — | — | CN | disclosed |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ECE1 2501/4885ALDH1A1 164/4885TDP1 3424/4885 |
| US-12024524-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | ECE1 2501/4885ALDH1A1 164/4885TDP1 3424/4885 |
| US-20080090863-A1 | Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor | MCHR1, GPR119, MCHR2 | ECE1 1571/4885ALDH1A1 1549/4885TDP1 2226/4885 |
| US-20120178751-A1 | 2-ARYLIMIDAZO[1,2-B]PYRIDAZINE, 2-PHENYLIMIDAZO[1,2-A]PYRIDINE, AND 2-PHENYLIMIDAZO[1,2-A]PYRAZINE DERIVATIVES | PRXL2A, CDK2, CCNA2 | ECE1 3733/4885ALDH1A1 334/4885TDP1 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.